AMGEN Inc

NASDAQ: AMGN
$319.29
+$2.38 (+0.8%)
Closing Price on November 5, 2024

AMGN Stock Chart and Intraday Price

AMGN Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 150,234.17M USD
Shares Outstanding 535,919,000
Amgen Inc. is a biotechnology pioneer focused on developing and delivering innovative human therapeutics. Its portfolio includes treatments for serious illnesses such as rheumatoid arthritis, psoriasis, osteoporosis, and various types of cancer. Among its well-known products are Enbrel, Otezla, Prolia, and Repatha. Amgen also collaborates with other pharmaceutical giants to enhance its product offerings, demonstrating a commitment to improving patient health globally. Founded in 1980, Amgen has grown to serve healthcare providers and patients worldwide from its headquarters in Thousand Oaks, California.

AMGN Articles

Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their shares into smaller slices. Walmart (NYSE:WMT) split its stock in February,...
Biotech investing is a thrill-a-minute ride. Biotech stocks can take investors soaring to new heights and fabulous wealth opportunities or send them into the pits of despair. The drug discovery...
These six top Dow Jones industrial average stocks are among the best dividend ideas for investors now, and all are rated Buy at top Wall Street firms. 
24/7 Wall St. Insights Jefferies is one of Wall Street’s fastest-growing firms. Since 1926, dividends have contributed approximately 32% of the total return for the S&P 500. Access 2 legendary,...
SCHD and VOO are two very popular ETFs for investors looking to diversify quickly. Like all ETFs, these two investment vehicles hold a “bucket” of stocks. However, the stocks they hold are very...
The artificial intelligence rally over the last year and a half, led by the so-called Magnificent 7, has been remarkable if you owned those stocks. However, most of the S&P 500 is treading water...
The Artificial Intelligence rally over the last year, led by the so-called “Magnificent 7,” has been fantastic if you owned those stocks. However, most of the S&P 500 is treading water and...
Fourth-quarter earnings kick off in a big way in 7 to 10 days, and earnings at some of the biggest and best U.S. companies are likely expected to decline for the third quarter running. Many top...
Here are some of the top upgrades, downgrades and other analyst calls for Thursday, December 21, along with other investing news.
Tuesday's most notable analyst upgrades and downgrades and other calls were on Amazon, PepsiCo, Netflix and more.
While many investment professionals suggest short Treasury paper and money markets, healthcare is the place in 2024 for long-term investors looking for growth and income. Demand is growing as the...
After years of a low-interest rate environment, which has reversed in a big way over the last 18 months, many investors continue to turn to equities not only for growth potential but also for solid...
While many Wall Street firms are suggesting short Treasury paper and money markets now, for long-term investors looking for growth and income, healthcare is the place to be for the rest of 2023 and...
Thursday's top analyst upgrades and downgrades included Amgen, Arista Networks, Boeing, Coherent, CSX, Netflix, Northrop Grumman, Shoals Technologies, Take-Two Interactive Software, Unilever and...
Tuesday's top analyst upgrades and downgrades included Airbnb, Amgen, Aramark, Arm, Datadog, Delta Air Lines, Match, Oracle, Patterson-UTI Energy, PayPal, Spotify Technology, Unity Software and...